gamma-aminobutyric acid type A receptor subunit gamma3Genealiases: []
Q-omics provides the consensus-scored GABRG3 profile across patient tissues and cancer cell-line models. GABRG3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GABRG3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GABRG3 RNA expression shows 14,402 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, KIRC, and GBM as cancer lineages where GABRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRG3 survival associations across molecular data types. GABRG3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRG3 RNA expression–survival associations across cancer types. High GABRG3 expression shows unfavorable associations in KICH, SKCM, LUAD and KIRC, but favorable associations in BLCA and THCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GABRG3 RNA expression.
This table summarizes GABRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GABRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRG3 shows lower tumor expression in KIRC, COAD and KICH and higher tumor expression in THCA, UCEC and HNSC. The KIRC box plot shows higher GABRG3 RNA expression in normal versus tumor tissue (log2 FC = −0.192, t-test p < 0.001).
This table shows molecular features associated with GABRG3 in patient tissues and cancer cell lines. In patient samples, GABRG3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
